FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of ...
DecisionDx-SCC test predicts local recurrence and metastasis in high-risk cutaneous squamous cell carcinoma, enhancing personalized treatment decisions. The test categorizes patients into three risk ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results